Alunbrig – brigatinib Tablets
Description
BRIGATINIB (ALUNBRIG) TABLETS – TREATMENT FOR ANAPLASTIC LYMPHOMA KINASE
Alunbrig 180mg has been shown to be effective as monotherapy in adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung malignant cancer (NSCLC) who had previously been treated with crizotinib.
This sign is approved under accelerated approval based on tumor reaction rate and duration of the reaction. An endorsement for this sign may be delayed pending confirmation and description of clinical benefit in a confirmatory trial.
 Monitoring and Testing While Taking Brigatinib :
While taking brigatinib, you will be checked by your specialist on a regular basis to monitor reactions and your response to treatment. Periodic blood work will be obtained to monitor your complete (total) blood count (CBC), fasting glucose, and CPK level, as well as the capacity of various organs (for example, your liver and pancreas). Your blood pressure and pulse rate will be measured (monitored).
Side Effects:
Increased levels of liver enzymes
Hyperglycemia (high blood sugar) (high blood sugar)
Creatine phosphokinase (CPK) activity has increased.
Increased levels of amylase and/or lipase (pancreatic enzymes)
Nausea
Anemia (low red blood cell count) (low red blood cell count)
Diarrhea
Fatigue
Cough
Constipation
Pain in the abdomen
Spasm of a muscle
Backache
Muscle ache
Joint discomfort
Fever
Numbness or tingling in the hands and/or feet
Insomnia (trouble sleeping) (trouble sleeping)
Leg ache
Visual modifications
